• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines.

作者信息

Lippert U, Krüger-Krasagakes S, Möller A, Kiessling U, Czarnetzki B M

机构信息

Department of Dermatology, Virchow Klinikum, Humboldt Universität, Berlin, Germany.

出版信息

Exp Dermatol. 1995 Aug;4(4 Pt 2):272-6. doi: 10.1111/j.1600-0625.1995.tb00257.x.

DOI:10.1111/j.1600-0625.1995.tb00257.x
PMID:8528601
Abstract

Mast cells and basophils are central effector cells of allergic reactions and are involved in inflammatory diseases. These cell types produce an array of mediators including a broad spectrum of cytokines. In order to examine whether antiallergic drugs modulate the release of these mediators, we have investigated the influence of dexamethasone and decarboethoxy-loratadine (DEL), the active metabolite of the H1-blocking agent loratadine, on the release of IL-6 and IL-8 by the human mast cell line HMC-1 and the human basophilic cell line KU812 by ELISA. Dexamethasone (10(-6)-10(-11) M) or Del (10(-5)-10(-14) M) were added to the cells either 1 h prior to or simultaneously with PMA and Ca-ionophore A23187. When preincubated with the cells, DEL dose-dependently suppressed IL-6 release by up to 40% and IL-8 release by up to 50%. Dexamethasone potently suppressed secretion of both cytokines if simultaneously added to the cells with the stimuli by up to 60% and after preincubation by up to 80%. Since both antihistamines and glucocorticoids are used for treatment of allergic diseases, the findings reported here indicate that these drugs may modulate allergic reactions via inhibition of cytokine release from mast cells and basophils.

摘要

相似文献

1
Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines.
Exp Dermatol. 1995 Aug;4(4 Pt 2):272-6. doi: 10.1111/j.1600-0625.1995.tb00257.x.
2
Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists.
Exp Dermatol. 2000 Apr;9(2):118-24. doi: 10.1034/j.1600-0625.2000.009002118.x.
3
[Effects of budesonide, desloratadine and dexamethasone on interleukine-4 release and expression from human mast cell line].
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2005 Feb;40(2):124-7.
4
Quantifying activity: a new assay reveals T-cell signalling in tiny skin biopsy samples.量化活性:一种新检测方法揭示微小皮肤活检样本中的T细胞信号传导。
Exp Dermatol. 2014 Jun;23(6):389-90. doi: 10.1111/exd.12387.
5
Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells.氯雷他定和去乙氧羰基氯雷他定可抑制人FcεRI⁺细胞介质的免疫释放。
Clin Exp Allergy. 1997 May;27(5):559-67. doi: 10.1046/j.1365-2222.1997.270860.x.
6
Production of interleukin-6 by human mast cells and basophilic cells.人肥大细胞和嗜碱性细胞产生白细胞介素-6。
J Invest Dermatol. 1996 Jan;106(1):75-9. doi: 10.1111/1523-1747.ep12327815.
7
Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine.地氯雷他定治疗对人嗜碱性粒细胞细胞因子生成和介质释放的抑制作用
Clin Exp Allergy. 2001 Sep;31(9):1369-77. doi: 10.1046/j.1365-2222.2001.01130.x.
8
Inhibitory effects of budesonide, desloratadine and dexamethasone on cytokine release from human mast cell line (HMC-1).布地奈德、地氯雷他定和地塞米松对人肥大细胞系(HMC-1)细胞因子释放的抑制作用。
Inflamm Res. 2004 Dec;53(12):664-9. doi: 10.1007/s00011-004-1309-6.
9
Inhibitory effect of the H1 antagonist loratadine on histamine release from human basophils.H1拮抗剂氯雷他定对人嗜碱性粒细胞组胺释放的抑制作用。
Int Arch Allergy Immunol. 1994 Sep;105(1):12-7. doi: 10.1159/000236797.
10
Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine.组胺H1拮抗剂去乙氧羰基氯雷他定在体外对人嗜碱性粒细胞中IgE介导和非IgE介导的组胺释放的抑制作用。
J Allergy Clin Immunol. 1994 Feb;93(2):494-500. doi: 10.1016/0091-6749(94)90359-x.

引用本文的文献

1
Association between desloratadine and prednisolone in the treatment of children with acute symptoms of allergic rhinitis: a double-blind, randomized and controlled clinical trial.地氯雷他定与泼尼松龙联合治疗儿童过敏性鼻炎急性症状的疗效观察:一项双盲、随机对照临床试验
Braz J Otorhinolaryngol. 2017 Nov-Dec;83(6):633-639. doi: 10.1016/j.bjorl.2016.08.009. Epub 2016 Sep 13.
2
Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence.第二代非镇静抗组胺药地氯雷他定的抗组胺、抗炎和抗过敏特性:证据回顾。
World Allergy Organ J. 2011 Feb;4(2):47-53. doi: 10.1097/WOX.0b013e3182093e19. Epub 2011 Feb 23.
3
Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells.
莫米松和地氯雷他定对上皮细胞嗜酸性粒细胞存活和细胞因子分泌的附加作用。
Respir Res. 2011 Feb 27;12(1):23. doi: 10.1186/1465-9921-12-23.
4
[Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series].[高剂量抗组胺疗法的止痒疗效。一项回顾性分析病例系列的结果]
Hautarzt. 2009 Jul;60(7):564-8. doi: 10.1007/s00105-009-1730-4.
5
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.地氯雷他定、非索非那定和左西替利嗪的临床药代动力学与药效学:一项比较性综述
Clin Pharmacokinet. 2008;47(4):217-30. doi: 10.2165/00003088-200847040-00001.
6
Synergistic action of famotidine and chlorpheniramine on acetic acid-induced chronic gastric ulcer in rats.法莫替丁与氯苯那敏对大鼠乙酸诱导的慢性胃溃疡的协同作用。
World J Gastroenterol. 2005 Dec 7;11(45):7203-7. doi: 10.3748/wjg.v11.i45.7203.
7
Increased bone fracture prevalence in postmenopausal women suffering from pollen-allergy.患有花粉过敏的绝经后女性骨折患病率增加。
Osteoporos Int. 2006;17(3):484-91. doi: 10.1007/s00198-005-0011-z. Epub 2006 Jan 24.
8
The safety and efficacy of desloratadine for the management of allergic disease.地氯雷他定治疗过敏性疾病的安全性和有效性。
Drug Saf. 2005;28(12):1101-18. doi: 10.2165/00002018-200528120-00005.
9
Desloratadine: an update of its efficacy in the management of allergic disorders.地氯雷他定:其在过敏性疾病管理中疗效的最新进展
Drugs. 2003;63(19):2051-77. doi: 10.2165/00003495-200363190-00010.
10
Selective early production of CCL20, or macrophage inflammatory protein 3alpha, by human mast cells in response to Pseudomonas aeruginosa.人肥大细胞对铜绿假单胞菌的反应中CCL20(即巨噬细胞炎性蛋白3α)的选择性早期产生
Infect Immun. 2003 Jan;71(1):365-73. doi: 10.1128/IAI.71.1.365-373.2003.